Abstract A212: Preclinical efficacy of MEK inhibition in a K-Ras driven cholangiocarcinoma preclinical model
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-a212
Abstract: Intrahepatic cholangiocarcinoma (iCCA) is a form of deadly malignancy with limited treatment options. Gain-of-function mutations in KRAS are one of the most frequent mutations, found in ~25% of human CCA patients. MEK inhibitors have been… read more here.
Keywords: krasv12 nicd; mek inhibitors; cca; model ... See more keywords